![](/wp-content/uploads/2018/10/bjyjtGMRGCKMmNdYOPjG.png)
$599
Why Lilly Will Terminate GGG; Lilly ADA 2021 Investor Update
Lilly hosted an ADA investor event in which the company covered tirzepatide, tri-agonist GGG, QW basal insulin, oral incretins, and a summary slide of Lilly’s CVRM R&D portfolio. Below, FENIX provides highlights and insights from the event, including why GGG won’t progress beyond Ph2.